论文部分内容阅读
目的探讨原发性高血压中miR-126是否可作为一种新的治疗靶点。方法 24只自发性高血压大鼠(SHR)随机分为4组,每周测量收缩压、舒张压、平均动脉压及心率。经过8周的病毒载体转染的处理,心、肾、脑、肝、肺组织被制成冰冻切片,通过荧光显微镜观察慢病毒载体在各个组织中的分布。应用ELISA试剂盒来测定血清NO含量。结果大鼠中下调miR-126无明显降血压的作用。结论通过下调miR-126来治疗原发性高血压并没有显著降血压的作用。高血压患者中miR-126表达的增加可能是由于一种代偿机制,具体机制有待进一步的研究。
Objective To investigate whether miR-126 can be used as a new therapeutic target in patients with essential hypertension. Methods Twenty-four spontaneous hypertensive rats (SHR) were randomly divided into 4 groups. Systolic pressure, diastolic pressure, mean arterial pressure and heart rate were measured weekly. After 8 weeks of viral vector transfection, heart, kidney, brain, liver and lung tissue were made into frozen sections, and the distribution of lentiviral vector in each tissue was observed by fluorescence microscopy. Serum NO levels were measured using ELISA kits. Results There was no significant antihypertensive effect of miR-126 in rats. Conclusion Treatment of essential hypertension by down-regulating miR-126 has no significant hypotensive effect. The increase of miR-126 expression in hypertensive patients may be due to a compensatory mechanism, the specific mechanism needs further study.